 BOSTON--BUSINESS WIRE--Gamida Cell Ltd. Nasdaq: GMDA, an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced that its previously announced public offering closed on December 21, 2020. The total number of ordinary shares sold by the Company in the offering was 9,343,750, inclusive of the full exercise of the underwriters option to purchase up to an additional 1,218,750 shares, at the public offering price of 8.00 per share, l 